David Drutz - 19 Nov 2021 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Director
Signature
/s/ William Brown, as Attorney-in-Fact
Issuer symbol
ALT
Transactions as of
19 Nov 2021
Net transactions value
+$168
Form type
4
Filing time
19 Nov 2021, 18:00:35 UTC
Previous filing
24 Sep 2021
Next filing
15 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALT Common Stock, par value $0.0001 Options Exercise $168 +70 +0.4% $2.40 17,673 19 Nov 2021 Direct
holding ALT Common Stock, par value $0.0001 333 19 Nov 2021 See Footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Stock Options (option to buy) Options Exercise $0 -70 -100% $0.000000* 0 19 Nov 2021 Common Stock, par value $0.0001 70 $2.40 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.
F2 This option was previously reported as covering 2,090 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018.
F3 This option is fully vested and exercisable as of the date hereof.